HRP20191707T1 - Depo formulacija hidrogel kompozita - Google Patents
Depo formulacija hidrogel kompozita Download PDFInfo
- Publication number
- HRP20191707T1 HRP20191707T1 HRP20191707T HRP20191707T1 HR P20191707 T1 HRP20191707 T1 HR P20191707T1 HR P20191707 T HRP20191707 T HR P20191707T HR P20191707 T1 HRP20191707 T1 HR P20191707T1
- Authority
- HR
- Croatia
- Prior art keywords
- mass
- depot formulation
- silica
- silica particles
- nucleotide
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 17
- 239000000203 mixture Substances 0.000 title claims 17
- 239000002131 composite material Substances 0.000 title claims 9
- 239000000017 hydrogel Substances 0.000 title claims 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 21
- 239000002777 nucleoside Chemical class 0.000 claims 7
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical class 0.000 claims 7
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 6
- 239000000377 silicon dioxide Substances 0.000 claims 4
- 238000001694 spray drying Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 claims 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 208000035415 Reinfection Diseases 0.000 claims 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims 1
- LLBBVHCLBXEPPD-UHFFFAOYSA-N [2-(2-methylidenecyclopentyl)-7h-purin-8-yl]methanol Chemical compound N=1C=C2NC(CO)=NC2=NC=1C1CCCC1=C LLBBVHCLBXEPPD-UHFFFAOYSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 229950005846 amdoxovir Drugs 0.000 claims 1
- 229950007936 apricitabine Drugs 0.000 claims 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 claims 1
- 238000005354 coacervation Methods 0.000 claims 1
- 238000010924 continuous production Methods 0.000 claims 1
- 229960002656 didanosine Drugs 0.000 claims 1
- 229950006528 elvucitabine Drugs 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 230000003534 oscillatory effect Effects 0.000 claims 1
- 238000005191 phase separation Methods 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 229960001203 stavudine Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229960000523 zalcitabine Drugs 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/329—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Claims (15)
1. Depo formulacija koja sadrži biorazgradiv silika hidrogel kompozit uključujući nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze, gdje se silika hidrogel kompozit može dobiti miješanjem
a) čestica silike koje sadrže navedeni nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze i koje imaju maksimalni promjer od ≤ 1 000 µm, kao takvih ili kao suspenzije, sa
b) silika solom
gdje
i) navedeni silika sol ima sadržaj čvrste materije od ≤ 5 mas-%,
ii) navedeni silika hidrogel kompozit sadrži do 85 mas-% navedenih silika čestica, i
iii) navedeni hidrogel kompozit ne teče i strukturno je stabilan kada se čuva u mirovanju i pseudoplastično teče kada je smicanje primijenjeno ubrizgavanjem.
2. Depo formulacija iz patentnog zahtjeva 1, naznačena time da silika hidrogel kompozit ne teče i strukturno je stabilan hidrogel na 37°C nakon što je smicanje primijenjeno ubrizgavanjem.
3. Depo formulacija iz patentnog zahtjeva 1 ili 2 naznačena time da silika sol ima sadržaj čvrste materije od ≤ 3 mas-%, poželjno ≤ 2 mas-% i najpoželjnije ≤ 1 mas-%.
4. Depo formulacija iz bilo kojeg od prethodnih patentnih zahtjeva naznačena time da silika čestice sadrže od 0.1 do 70 mas-%, poželjno od 0.3 do 50 mas-%, i najpoželjnije od 1 do 15 mas-% inkorporiranog nukleotidnog ili nukleozidnog analoga inhibitora reverzne transkriptaze.
5. Depo formulacija iz bilo kojeg od prethodnih patentnih zahtjeva naznačena time da su silika čestice mikročestice koje imaju promjer između 0.5 µm i 300 µm, poželjno 0.5 µm i 100 µm, poželjnije 0.5 µm i 30 µm i najpoželjnije 0.5 µm i 20 µm.
6. Depo formulacija iz patentnog zahtjeva 5 naznačena time da volumenska frakcija silika čestica koje imaju promjer < 1 µm je < 3 %, poželjno < 2 %, i najpoželjnije < 1 zapreminskog-%.
7. Depo formulacija iz bilo kojeg od prethodnih patentnih zahtjeva naznačena time da hidrogel kompozit sadrži od do 80 mas-%, poželjno 10 do 80 mas-%, najpoželjnije 20 do 60 mas-% silika čestica.
8. Depo formulacija iz bilo kojeg od prethodnih patentnih zahtjeva naznačena time da sadržaj čvrste materije kompozita je od 10 mas-% do 75 mas-%, poželjno od 15 mas-% do 60 mas-% i najpoželjnije od 25 mas-% do 55 mas-%.
9. Depo formulacija iz bilo kojeg od prethodnih patentnih zahtjeva naznačena time da
- složeni modul izmjeren pod malim kutom oscilatornog smicanja u linearnom viskoelastičnom regionu je < 2400 kPa, poželjno < 1200 kPa i najpoželjnije < 600 kPa,
i/ili
- faktor gubitka, tj. viskozni modul/elastični modul, je < 1, poželjno < 0.8 i najpoželjnije < 0.6, i/ili
- viskozitet je 10-50 Pas izmjerena stopom smicanja od 10-50 s-1, viskozitet je 0.4-1.5 Pas izmjerena stopom smicanja od 200-210 s-1, i 0.1-0.4 Pas izmjerena stopom smicanja od 600-610 s-1.
10. Depo formulacija iz bilo kojeg od prethodnih patentnih zahtjeva naznačena time da su silika čestice dobivene procesom odabranim od sušenje raspršivanjem, jednostruka emulzija, dvostruka emulzija, polimerizacija, fazno razdvajanje koacervacijom i metode ekstakcije rastvarača, poželjno sušenje raspršivanjem, najpoželjnije sušenje raspršivanjem sa neprekidnim odvajanjem čestica pomoću ciklonskog separatora.
11. Depo formulacija u skladu sa patentnim zahtjevom 10 naznačena time da nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze, sadržan u česticama silike, je inkorporiran u česticama silike koristeći kontinuirani proces unutar cijevnog reaktora gdje se navedeni nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze i silika sol kontinuirano dopremaju kao odvojeni tokovi unutar i kombiniraju u navedenom reaktoru, zatim se kontinuirano odvode iz navedenog cijevnog reaktora i u proces kontinuiranog sušenja raspršivanjem sa neprekidnim odvajanjem čestica pomoću ciklonskog separatora.
12. Depo formulacija u skladu sa bilo kojim od prethodnih patentnih zahtjeva naznačena time da nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze je odabran od grupe koja se sastoji od
- dideoksinukleozida, i/ili
- zidovudina, didanozina, zalcitabina, stavudina, lamivudin abakavira, emtricitabina, entekavira, tenofovira, adefovira, apricitabina, elvucitabina, amdoksovira i racivira, poželjno entekavira.
13. Depo formulacija u skladu sa bilo kojim od prethodnih patentnih zahtjeva naznačena time da nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze je analog deoksiguanozina, poželjno odabran iz grupe koja se sastoji od hidroksimetil(metilenciklopentil)purina i pirimidina.
14. Depo formulacija u skladu sa bilo kojim od prethodnih patentnih zahtjeva naznačena time da je odabrana iz grupe koja se sastoji od formulacija koje se mogu ubrizgati i implantabilnih formulacija, poželjno koje se mogu ubrizgati.
15. Depo formulacija u skladu sa bilo kojim od prethodnih patentnih zahtjeva za primjenu u liječenju kroničnih virusnih infekcija i prevenciji kronične virusne reinfekcije poželjno odabrane od grupe infekcija koja se sastoji od hepatitisa B i HIV infekcija, i najpoželjnije grupe koja se sastoji od infekcija hepatitisom B.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20155750 | 2015-10-22 | ||
| PCT/FI2016/050745 WO2017068245A1 (en) | 2015-10-22 | 2016-10-21 | Hydrogel composite depot formulation |
| EP16794670.6A EP3365020B1 (en) | 2015-10-22 | 2016-10-21 | Hydrogel composite depot formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191707T1 true HRP20191707T1 (hr) | 2019-12-13 |
Family
ID=57286528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191707 HRP20191707T1 (hr) | 2015-10-22 | 2019-09-20 | Depo formulacija hidrogel kompozita |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10172792B2 (hr) |
| EP (1) | EP3365020B1 (hr) |
| JP (1) | JP6905520B2 (hr) |
| KR (1) | KR102228986B1 (hr) |
| CN (1) | CN108367076B (hr) |
| AU (1) | AU2016342470B2 (hr) |
| BR (1) | BR112018006784B1 (hr) |
| CA (1) | CA3001752C (hr) |
| DK (1) | DK3365020T3 (hr) |
| ES (1) | ES2748032T3 (hr) |
| HR (1) | HRP20191707T1 (hr) |
| HU (1) | HUE046419T2 (hr) |
| LT (1) | LT3365020T (hr) |
| MX (1) | MX2018004797A (hr) |
| PL (1) | PL3365020T3 (hr) |
| PT (1) | PT3365020T (hr) |
| WO (1) | WO2017068245A1 (hr) |
| ZA (1) | ZA201802040B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023532778A (ja) | 2020-07-07 | 2023-07-31 | デルシテック オサケユイチア | シリカハイドロゲルコンポジットおよびその使用 |
| CA3214619A1 (en) * | 2021-04-07 | 2022-10-13 | Martin P. Redmon | Silica-based formulations of therapeutic oliogpeptides and peptidomimetics |
| WO2024047230A1 (en) | 2022-09-01 | 2024-03-07 | Optifye Therapeutics Ag | Ophthalmic compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4322315B2 (ja) | 1996-05-29 | 2009-08-26 | デルシテク オサケ ユキチュア | 生物学的適用のための溶解性酸化物 |
| CN101541939A (zh) * | 2006-11-22 | 2009-09-23 | 阿普尔顿纸张公司 | 含有益剂的递送颗粒 |
| CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
| US8974709B2 (en) * | 2010-06-25 | 2015-03-10 | Colabs Intl Corp | Ceramic encapsulation with controlled layering by use of prehydrolyzed functionalized silanes |
| US9579283B2 (en) * | 2011-04-28 | 2017-02-28 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| KR101594820B1 (ko) | 2011-06-16 | 2016-02-17 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
| ITTO20111242A1 (it) * | 2011-12-30 | 2013-07-01 | Miso S R L | Composizioni per il trattamento di patologie delle mucose |
| DK3013317T3 (da) | 2013-06-24 | 2020-02-17 | Delsitech Oy | Silicahydrogelkomposit |
| JP2016527308A (ja) | 2013-08-06 | 2016-09-08 | ドン クック ファーマシューティカル カンパニー リミテッド | エンテカビル微小球及びこれを含む非経口投与用医薬組成物 |
-
2016
- 2016-10-21 LT LT16794670T patent/LT3365020T/lt unknown
- 2016-10-21 MX MX2018004797A patent/MX2018004797A/es active IP Right Grant
- 2016-10-21 CN CN201680061622.2A patent/CN108367076B/zh active Active
- 2016-10-21 HU HUE16794670A patent/HUE046419T2/hu unknown
- 2016-10-21 KR KR1020187008781A patent/KR102228986B1/ko active IP Right Grant
- 2016-10-21 PL PL16794670T patent/PL3365020T3/pl unknown
- 2016-10-21 CA CA3001752A patent/CA3001752C/en active Active
- 2016-10-21 WO PCT/FI2016/050745 patent/WO2017068245A1/en active Application Filing
- 2016-10-21 JP JP2018520484A patent/JP6905520B2/ja active Active
- 2016-10-21 US US15/770,034 patent/US10172792B2/en active Active
- 2016-10-21 DK DK16794670.6T patent/DK3365020T3/da active
- 2016-10-21 PT PT167946706T patent/PT3365020T/pt unknown
- 2016-10-21 EP EP16794670.6A patent/EP3365020B1/en active Active
- 2016-10-21 ES ES16794670T patent/ES2748032T3/es active Active
- 2016-10-21 BR BR112018006784-9A patent/BR112018006784B1/pt active IP Right Grant
- 2016-10-21 AU AU2016342470A patent/AU2016342470B2/en active Active
-
2018
- 2018-03-27 ZA ZA2018/02040A patent/ZA201802040B/en unknown
-
2019
- 2019-09-20 HR HRP20191707 patent/HRP20191707T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6905520B2 (ja) | 2021-07-21 |
| CA3001752A1 (en) | 2017-04-27 |
| AU2016342470B2 (en) | 2019-03-21 |
| ES2748032T3 (es) | 2020-03-12 |
| AU2016342470A1 (en) | 2018-04-12 |
| US10172792B2 (en) | 2019-01-08 |
| WO2017068245A1 (en) | 2017-04-27 |
| PT3365020T (pt) | 2019-10-24 |
| US20180311150A1 (en) | 2018-11-01 |
| PL3365020T3 (pl) | 2020-03-31 |
| EP3365020A1 (en) | 2018-08-29 |
| HUE046419T2 (hu) | 2020-02-28 |
| EP3365020B1 (en) | 2019-07-17 |
| BR112018006784B1 (pt) | 2023-10-03 |
| DK3365020T3 (da) | 2019-10-07 |
| MX2018004797A (es) | 2018-09-06 |
| KR102228986B1 (ko) | 2021-03-18 |
| CA3001752C (en) | 2021-10-05 |
| BR112018006784A2 (pt) | 2018-10-16 |
| CN108367076A (zh) | 2018-08-03 |
| LT3365020T (lt) | 2019-10-25 |
| ZA201802040B (en) | 2019-07-31 |
| CN108367076B (zh) | 2021-08-31 |
| JP2018531270A (ja) | 2018-10-25 |
| KR20180071253A (ko) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191707T1 (hr) | Depo formulacija hidrogel kompozita | |
| JP2020521805A (ja) | 安全性および貯蔵安定性が向上した生分解性微粒球の製造方法 | |
| DE60325709D1 (de) | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen | |
| HRP20200327T1 (hr) | Neurozaštitan sastav koji obuhvaća polygalae, astragali, chuanxiong i angelicu sinensis | |
| MX2018006919A (es) | Composiciones de emulsion inversas. | |
| RU2015114444A (ru) | Печатный материал | |
| WO2008144288A8 (en) | Apparatus and methods for preparation of subtantially uniform emulsions containing a particle | |
| JP2018531270A5 (hr) | ||
| JP2015205894A5 (hr) | ||
| AR052297A1 (es) | Composiciones de confiteria con material de relleno central | |
| JP2014218437A5 (hr) | ||
| Stanimirova et al. | Competitive adsorption of the protein hydrophobin and an ionic surfactant: Parallel vs sequential adsorption and dilatational rheology | |
| JP2015046256A5 (hr) | ||
| FI3463325T3 (fi) | Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä | |
| Pawatekar et al. | A Review on sintering method in pharmaceutical sciences | |
| JP2005526187A5 (hr) | ||
| JP7314303B2 (ja) | カールマスカラ組成物 | |
| Khoufech et al. | Influence of liquid formulation and impact conditions on the wetting of hydrophobic surfaces by aqueous polymeric solutions | |
| RU2019122799A (ru) | Композиции загущенных органических жидкостей с полимерными модификаторами реологии | |
| CN103938437B (zh) | 一种纺织染整用乳化剂 | |
| RU2017101050A (ru) | Композиции и способы повышения эффективности местного нанесения окрашенного косметического средства | |
| RU2017144564A (ru) | Капсулы на основе капецитабина с пролонгированным высвобождением | |
| CN102432231B (zh) | 建筑用粉末胶粘剂 | |
| RU2017142726A (ru) | Офтальмическая композиция, содержащая липоевую кислоту и мукомиметический полимер | |
| US10864386B2 (en) | Compositions comprising solvent, a monoalcohol and glycerin |